Loading clinical trials...
Loading clinical trials...
An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade
Conditions
Interventions
CCX168
Locations
6
United States
Palo Alto, California, United States
San Francisco, California, United States
Reno, Nevada, United States
Chapel Hill, North Carolina, United States
Columbus, Ohio, United States
Stockholm, Sweden
Start Date
March 27, 2015
Primary Completion Date
September 13, 2015
Completion Date
June 1, 2018
Last Updated
March 13, 2025
NCT07375758
NCT06291376
NCT06466135
NCT05248646
NCT05852938
NCT04663204
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions